None, 184
Platinum, 28
Radiation therapy, 22
Selumetinib, 21
Dabrafenib + Trametinib, 18
Bevacizumab + Olaparib, 18
ncit:None and PI3Ka/Di, 9
Durvalumab, 8
Entrectinib, 7
Erdafitinib, 6
Proton-based SBRT, 6
ncit:None and PI-103, 6
Tazemetostat, 5
ncit:C15632 and Chemotherapy, 5
ncit:None and JQ1, 5
ncit:None and SU11274, 5
Gamma knife, 4
U0126, 4
MK-2206, 4
Ipilimumab + Vemurafenib, 4
Capmatinib, 4
Alkylating chemotherapy, 4
Neoadjuvant chemoradiation, 4
nutlin-3, 4
Talazoparib, 4
Lapatinib + Trastuzumab, 4
Neoadjuvant chemotherapy + surgery, 4
ncit:None and PD173074, 4
Larotrectinib, 3
Selpercatinib, 3
Pralsetinib, 3
ncit:None and RDEA 119, 3
ncit:None and EAP Protocol, 3
JQ1, 2
Pemigatinib, 2
Azacitidine + Panobinostat, 2
Encorafenib, 2
Cetuximab + Encorafenib, 2
Cobimetinib + Vemurafenib, 2
Selumetinib + Vemurafenib, 2
Mito-CP, 2
Trametinib + Vemurafenib, 2
Interferon-alpha + Ixazomib, 2
GANT61, 2
GANT61 + Obatoclax, 2
Neratinib + Vemurafenib, 2
Cetuximab + Vemurafenib, 2
Nivolumab + Pembrolizumab, 2
Durvalumab + Osimertinib, 2
Durvalumab + Gefitinib, 2
Ado-Trastuzumab Emtansine, 2
Letrozole + Tamoxifen, 2
Palbociclib + Trametinib, 2
Buparlisib + Trametinib, 2
FGFR1 inhibitor + Trametinib, 2
FGFR1 inhibitor + Trametinib , 2
SBRT, 2
SU11274, 2
EXEL-8232, 2
Chemotherapy + Pembrolizumab, 2
EPZ015666, 2
Pertuzumab + Trastuzumab, 2
Chemotherapy + Trastuzumab, 2
Capecitabine + Trastuzumab + Tucatinib, 2
Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab, 2
Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab, 2
Margetuximab-cmkb + Chemotherapy, 2
Carbogen and nicotinamide  + radiotherapy, 2
Radical radiotherapy, 2
Ipilimumab + Nivolumab, 2
ncit:None and SU5614, 2
ncit:None and AGI-5198, 2
ncit:C15360 and Adjuvant Chemotherapy, 2
ncit:None and Spliceostatin A, 2
ncit:None and GSK126, 2
ncit:None and PI103, 2
ncit:None and BPTES, 2
ncit:None and JQ-1, 2
ncit:None and U0126, 2
ncit:C154898 and Inhibitor, 2
ncit:None and R3Mab, 2
ncit:None and FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074, 2
Lorlatinib, 1
Omacetaxine, 1
Dacomitinib, 1
Ivosidenib, 1
Alpelisib, 1
Atezolizumab, 1
ncit:None and Anti-CD33, 1
ncit:None and NSC348884, 1
ncit:C158876 and Induction Therapy, 1
ncit:None and JW55, 1
ncit:None and G007-LK, 1
ncit:C11197 and FOLFOX Regimen, 1
ncit:None and GSK321, 1
ncit:None and SB202190, 1
ncit:None and AKTi-1/2, 1
ncit:None and WZ4002, 1
ncit:None and JSI-124, 1
ncit:None and NOTCH1 Antibody (PF-06293622), 1
ncit:None and RG7356, 1
ncit:None and GNE-617, 1
ncit:None and ACLY SiRNA, 1
ncit:C1490 and Taxane Compound, 1
ncit:None and IGF1R Monoclonal Antibody, 1
ncit:None and OICR-9429, 1
ncit:None and AZD5438, 1
ncit:None and WHI-P154, 1
ncit:None and 2,4-pyrimidinediamine, 1
ncit:None and AZD3463, 1
ncit:None and A66, 1
ncit:None and Tgx 221, 1
ncit:None and JQ1 Compound, 1
ncit:None and GPI-15427, 1
ncit:None and C646, 1
ncit:None and UO126, 1
ncit:None and UNC1062, 1
ncit:C15313 and Radiation Therapy, 1
ncit:C2462 and Radioactive Iodine, 1
ncit:None and NVP-AEW541, 1
ncit:None and ARS-1620, 1
ncit:None and ALK2 Inhibitor LDN-193189, 1
ncit:None and JQEZ5, 1
ncit:None and CHZ868, 1
ncit:None and JAK Inhibitor I, 1
ncit:None and DS-6501b, 1
ncit:None and MAP855, 1
ncit:None and EPZ004777, 1
ncit:None and CHMFL-KIT-031, 1
ncit:None and EPZ011989, 1
